Clicky

Provention Bio, Inc.(PRVB)

Description: Provention Bio, Inc. is a clinical-stage biopharmaceutical company that develops therapeutics targeting immune-mediated diseases. The Company aims at developing therapies for disease that include type one diabetes (T1D), Crohn’s disease, ulcerative colitis, lupus and other viral diseases. The Company’s principal product candidates include PRV-031, PRV-6527, PRV-300, PRV-3279, and PRV-0101.PRV-031 is a product candidate in its Phase III clinical trial that is developed for the interception of T1D. PRV-6527 is an oral CSF-1R inhibitor for the treatment of Crohn’s disease. PRV-300 is developed for the treatment of ulcerative colitis. PRV-3279 is developed to treat lupus disease. PRV-101 is a multivalent coxsackie virus (CVB) vaccine for the prevention of acute CVB and the prevention of the onset of T1D.


Keywords: Medicine Biopharmaceutical Disease Diabetes Immunology Autoimmune Disease Ulcer Ulcerative Colitis Crohn's Disease Diarrhea Colitis Abdominal Pain Viral Disease Lupus Immune Mediated Diseases

Home Page: www.proventionbio.com

PRVB Technical Analysis

55 Broad Street
Red Bank, NJ 07701
United States
Phone: 908 336 0360


Officers

Name Title
Mr. Ashleigh W. Palmer B.Sc., M.B.A. Co-Founder, Pres, CEO & Director
Mr. Thierry Chauche Chief Financial Officer
Dr. Eleanor L. Ramos M.D. Chief Medical Officer
Dr. Francisco Leon M.D., Ph.D. Co-Founder & Chief Scientific Officer
Ms. Christina Yi Chief Operations Officer
Mr. Robert A. Doody Jr. VP of Investor Relations
Ms. Heidy Abreu King-Jones J.D., L.L.M. Chief Legal Officer
Kaelan Hollon VP of Corp. Communications
Mr. Jason Levine VP Marketing
Sarah O'Brien Chief People Officer

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 5.3121
Price-to-Sales TTM: 289.7011
IPO Date: 2018-07-24
Fiscal Year End: December
Full Time Employees: 82
Back to stocks